BRENDA - Enzyme Database

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respsct to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

Boffa, M.B.; Wang, W.; Bajzar, l.; Nesheim, M.E.; J. Biol. Chem. 273, 2127-2135 (1998)

Data extracted from this reference:

Activating Compound
EC Number
Activating Compound
Commentary
Organism
Structure
3.4.17.20
thrombin
activation
Homo sapiens
3.4.17.20
Thrombomodulin
activation
Homo sapiens
Cloned(Commentary)
EC Number
Cloned (Commentary)
Organism
3.4.17.20
expression in BHK-cells
Homo sapiens
Inhibitors
EC Number
Inhibitors
Commentary
Organism
Structure
3.4.17.20
2-Guanidinoethylmercaptosuccinic acid
i.e. GEMSA
Homo sapiens
3.4.17.20
6-aminohexanoic acid
-
Homo sapiens
3.4.17.20
potato carboxypeptidase inhibitor
-
Homo sapiens
KM Value [mM]
EC Number
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
3.4.17.20
3.41
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
4.71
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
766
-
Hippuryl-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
783
-
hippuryl-L-Arg
recombinant enzyme
Homo sapiens
3.4.17.20
817
-
hippuryl-L-Arg
plasma-derived enzyme
Homo sapiens
3.4.17.20
933
-
Hippuryl-L-Lys
recombinant enzyme
Homo sapiens
Molecular Weight [Da]
EC Number
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
3.4.17.20
12000
-
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
25000
-
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
35000
-
x * 35000, active enzyme
Homo sapiens
3.4.17.20
46000
-
x * 46000, enzymes rTAFI and pTAFI, deglycosylated enzymes, slight differences in MW might be due to differences in glycosylation, SDS-PAGE
Homo sapiens
Natural Substrates/ Products (Substrates)
EC Number
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
ID
3.4.17.20
Fibrin, partially degraded + H2O
Homo sapiens
-
?
-
-
?
Organism
EC Number
Organism
UniProt
Commentary
Textmining
3.4.17.20
Homo sapiens
-
-
-
Purification (Commentary)
EC Number
Purification (Commentary)
Organism
3.4.17.20
of cloned enzyme from BHK-cells
Homo sapiens
Source Tissue
EC Number
Source Tissue
Commentary
Organism
Textmining
3.4.17.20
plasma
-
Homo sapiens
-
Specific Activity [micromol/min/mg]
EC Number
Specific Activity Minimum [µmol/min/mg]
Specific Activity Maximum [µmol/min/mg]
Commentary
Organism
3.4.17.20
0.017
-
substrate hippuryl-L-Arg
Homo sapiens
Substrates and Products (Substrate)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
Substrate Product ID
3.4.17.20
Fibrin, partially degraded + H2O
-
28933
Homo sapiens
Fibrin, partially degraded + L-Lys + L-Arg
-
28933
Homo sapiens
?
3.4.17.20
Fibrin, partially degraded + H2O
-
28933
Homo sapiens
?
-
-
-
?
3.4.17.20
Hippuryl-L-Arg + H2O
-
28933
Homo sapiens
Hippuric acid + L-Arg
-
28933
Homo sapiens
?
3.4.17.20
Hippuryl-L-Lys + H2O
-
28933
Homo sapiens
Hippuric acid + L-Lys
-
28933
Homo sapiens
?
3.4.17.20
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys + H2O
-
28933
Homo sapiens
N-[3-(2-Furylacryloyl)]-L-Ala + L-Lys
-
28933
Homo sapiens
?
Subunits
EC Number
Subunits
Commentary
Organism
3.4.17.20
?
derived from zymogen by cleavage at Arg92, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 46000, enzymes rTAFI and pTAFI, deglycosylated enzymes, slight differences in MW might be due to differences in glycosylation, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 35000, active enzyme
Homo sapiens
Temperature Stability [°C]
EC Number
Temperature Stability Minimum [°C]
Temperature Stability Maximum [°C]
Commentary
Organism
3.4.17.20
-
-
enzyme pTAFI and rTAFI stable
Homo sapiens
3.4.17.20
22
-
half-life 120-150 min
Homo sapiens
3.4.17.20
30
-
half-life 40-50 min
Homo sapiens
3.4.17.20
37
-
half-life 8-9 min, stable in presence of inhibitors 2-guanidinoethylmercaptosuccinic acid or 6-aminohexanoic acid
Homo sapiens
Turnover Number [1/s]
EC Number
Turnover Number Minimum [1/s]
Turnover Number Maximum [1/s]
Substrate
Commentary
Organism
Structure
3.4.17.20
40.7
-
Hippuryl-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
45.6
-
Hippuryl-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
52.4
-
hippuryl-L-Arg
plasma-derived enzyme
Homo sapiens
3.4.17.20
56.7
-
hippuryl-L-Arg
recombinant enzyme
Homo sapiens
3.4.17.20
248
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
293
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
plasma-derived enzyme
Homo sapiens
Activating Compound (protein specific)
EC Number
Activating Compound
Commentary
Organism
Structure
3.4.17.20
thrombin
activation
Homo sapiens
3.4.17.20
Thrombomodulin
activation
Homo sapiens
Cloned(Commentary) (protein specific)
EC Number
Commentary
Organism
3.4.17.20
expression in BHK-cells
Homo sapiens
Inhibitors (protein specific)
EC Number
Inhibitors
Commentary
Organism
Structure
3.4.17.20
2-Guanidinoethylmercaptosuccinic acid
i.e. GEMSA
Homo sapiens
3.4.17.20
6-aminohexanoic acid
-
Homo sapiens
3.4.17.20
potato carboxypeptidase inhibitor
-
Homo sapiens
KM Value [mM] (protein specific)
EC Number
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
3.4.17.20
3.41
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
4.71
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
766
-
Hippuryl-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
783
-
hippuryl-L-Arg
recombinant enzyme
Homo sapiens
3.4.17.20
817
-
hippuryl-L-Arg
plasma-derived enzyme
Homo sapiens
3.4.17.20
933
-
Hippuryl-L-Lys
recombinant enzyme
Homo sapiens
Molecular Weight [Da] (protein specific)
EC Number
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
3.4.17.20
12000
-
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
25000
-
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
35000
-
x * 35000, active enzyme
Homo sapiens
3.4.17.20
46000
-
x * 46000, enzymes rTAFI and pTAFI, deglycosylated enzymes, slight differences in MW might be due to differences in glycosylation, SDS-PAGE
Homo sapiens
Natural Substrates/ Products (Substrates) (protein specific)
EC Number
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
ID
3.4.17.20
Fibrin, partially degraded + H2O
Homo sapiens
-
?
-
-
?
Purification (Commentary) (protein specific)
EC Number
Commentary
Organism
3.4.17.20
of cloned enzyme from BHK-cells
Homo sapiens
Source Tissue (protein specific)
EC Number
Source Tissue
Commentary
Organism
Textmining
3.4.17.20
plasma
-
Homo sapiens
-
Specific Activity [micromol/min/mg] (protein specific)
EC Number
Specific Activity Minimum [µmol/min/mg]
Specific Activity Maximum [µmol/min/mg]
Commentary
Organism
3.4.17.20
0.017
-
substrate hippuryl-L-Arg
Homo sapiens
Substrates and Products (Substrate) (protein specific)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
ID
3.4.17.20
Fibrin, partially degraded + H2O
-
28933
Homo sapiens
Fibrin, partially degraded + L-Lys + L-Arg
-
28933
Homo sapiens
?
3.4.17.20
Fibrin, partially degraded + H2O
-
28933
Homo sapiens
?
-
-
-
?
3.4.17.20
Hippuryl-L-Arg + H2O
-
28933
Homo sapiens
Hippuric acid + L-Arg
-
28933
Homo sapiens
?
3.4.17.20
Hippuryl-L-Lys + H2O
-
28933
Homo sapiens
Hippuric acid + L-Lys
-
28933
Homo sapiens
?
3.4.17.20
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys + H2O
-
28933
Homo sapiens
N-[3-(2-Furylacryloyl)]-L-Ala + L-Lys
-
28933
Homo sapiens
?
Subunits (protein specific)
EC Number
Subunits
Commentary
Organism
3.4.17.20
?
derived from zymogen by cleavage at Arg92, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 25000 + x * 12000, derived by cleavage at Arg330, inactive form, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 46000, enzymes rTAFI and pTAFI, deglycosylated enzymes, slight differences in MW might be due to differences in glycosylation, SDS-PAGE
Homo sapiens
3.4.17.20
?
x * 35000, active enzyme
Homo sapiens
Temperature Stability [°C] (protein specific)
EC Number
Temperature Stability Minimum [°C]
Temperature Stability Maximum [°C]
Commentary
Organism
3.4.17.20
-
-
enzyme pTAFI and rTAFI stable
Homo sapiens
3.4.17.20
22
-
half-life 120-150 min
Homo sapiens
3.4.17.20
30
-
half-life 40-50 min
Homo sapiens
3.4.17.20
37
-
half-life 8-9 min, stable in presence of inhibitors 2-guanidinoethylmercaptosuccinic acid or 6-aminohexanoic acid
Homo sapiens
Turnover Number [1/s] (protein specific)
EC Number
Turnover Number Minimum [1/s]
Turnover Number Maximum [1/s]
Substrate
Commentary
Organism
Structure
3.4.17.20
40.7
-
Hippuryl-L-Lys
plasma-derived enzyme
Homo sapiens
3.4.17.20
45.6
-
Hippuryl-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
52.4
-
hippuryl-L-Arg
plasma-derived enzyme
Homo sapiens
3.4.17.20
56.7
-
hippuryl-L-Arg
recombinant enzyme
Homo sapiens
3.4.17.20
248
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
recombinant enzyme
Homo sapiens
3.4.17.20
293
-
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys
plasma-derived enzyme
Homo sapiens